Modernatx, Inc
Research
The register writes this name in capitals: MODERNATX, INC.
- Sector
- Companies
- Agreements as applicant
- 2
- In term in September 2026
- 0
- Distinct datasets
- 1
- Files released
- 0
- Latest agreement end date
- 23 May 2024
Sector set by hand: A company, which the register files as Research. See data/organisation-sectors.json in the repository.
Files released counts only files released externally by DARS. Access granted in NHS England's own systems, such as its Secure Data Environment, is not included.
Agreements
| Agreement | Datasets | Files | Latest term | Status | Commercial |
|---|---|---|---|---|---|
| PERMISSION TO CONTACT - VRR - NextCOVE Study: A randomized, observer-blind, active-controlled Phase 3 study to investigate the safety, immunogenicity, and relative vaccine efficacy of mRNA-1283.222 as a booster dose compared with mRNA-1273.222 in participants aged 12 years+ to prevent CV-19 DARS-NIC-705821-P6J0H | 1 | 0 | 24 May 2023 to 23 May 2024 | Expired | Yes |
| A Phase 2/3, Randomized, Stratified, Observer-blind Study to Evaluate the Immunogenicity and Safety of mRNA-1273.529 (B.1.1.529, Omicron variant) in Comparison with mRNA-1273 (prototype) Booster Vaccine DARS-NIC-623799-T2J4F | 1 | 0 | 17 February 2022 to 16 February 2023 | Expired | Yes |
Datasets named in its agreements
Cite this page
NHS England (2026) Data Uses Register, September 2026 edition, agreements naming Modernatx, Inc. Read via NHS Data Access Explorer (unofficial), https://healthdatauses.uk/organisations/modernatx-inc/ (accessed [date]).
This address stays the same, but the page is rebuilt with each monthly edition, so the citation names the edition it shows. Every edition's data is kept in the facts store.